Hold the Line, Widen the Path
Eight cross-functional Life & Health reinsurance simulations built for improvisation: rich context, asymmetric role information, meaningful constraints, and multiple defensible outcomes.
NorthBridge Life is preparing a significant new US individual life placement. Over the past two years it has invested heavily in metabolic-health programmes, and GLP-1 use among eligible customers has increased substantially. The broker has shared an indication from another reinsurer that appears to recognise materially more future mortality improvement than Swiss Re’s current position.
Swiss Re’s Pricing team agrees that GLP-1 therapies and broader metabolic-health improvement could change mortality over time. NorthBridge has supplied aggregate data showing increased GLP-1 use and improvements in some metabolic measures, but information on adherence, discontinuation, underlying health status, and persistence is incomplete.
Swiss Re’s quotation is approximately five basis points above the competing indication. Final indications are due in three days. The room must decide whether any economic recognition is possible now, what remains a mortality judgment, and what evidence or experience would justify movement later.
The group can recommend a permanent price change, a bounded commercial or structural response, a reviewable mechanism, or a decision to hold the current position. The purpose is to make the trade-off explicit rather than to discover one hidden correct answer.
Which statements were evidence, which were forecasts, and which were appetite or commercial choices? What information did each role need from the others before it could move?
Suggested time: 8 minutes preparation, 10 minutes conversation, 7 minutes debrief.
Pricing Actuary — Swiss Re
You lead the mortality pricing work. You agree that GLP-1 therapies and broader metabolic-health change could improve future mortality, but you do not believe the full improvement implied by the competing indication can be recognised today.
Information you hold
- GLP-1 use is not the same as sustained adherence.
- Improvement from an unhealthy baseline is not automatically improvement relative to the mortality already assumed for an insured population.
- Short-term observed change is not the same as durable mortality improvement over many years.
- NorthBridge’s aggregate data does not yet separate these cleanly.
- You have already recognised a modest amount of emerging improvement in the current view.
What matters to you
The mortality view must remain independently defensible. You do not want Swiss Re to become so cautious that it systematically fails to recognise genuine changes in risk.
What you can move on
You are open to different ways of recognising improvement over time, including better data, a defined review path, experience sharing, or another mechanism that lets economics respond as evidence matures.
Your constraint
You cannot change the mortality assumption simply to eliminate a competitive price gap. A commercial decision to accept a lower return may be legitimate, but it must not be represented as a different mortality conclusion.
What you need to learn
Which data NorthBridge can provide, what the client actually needs to demonstrate to its board, and whether the proposed economic recognition belongs in Cost, Price, or a structure connecting the two.
Senior Client Manager — Swiss Re
You own the NorthBridge relationship. The issue matters to the client beyond five basis points: leadership has invested heavily in metabolic health and believes it is building a healthier portfolio. They feel they are supplying the kind of data and prevention the industry asked for while Swiss Re is still asking them to wait.
Information you hold
- The competing indication is credible enough for NorthBridge to use.
- NorthBridge would prefer Swiss Re because of the broader relationship.
- NorthBridge’s Chief Actuary will struggle to defend a materially more expensive quote to the board.
- The client’s underlying need is economic recognition for its investment; the exact mechanism has not been fixed.
What matters to you
Swiss Re needs to look capable of responding to change, not merely explaining why established assumptions remain safer. You also need to avoid a price that wins today and looks indefensible when experience emerges.
What you can move on
You can explore timing, data access, review mechanics, experience sharing, a bounded credit, or other commercial terms. You can translate the technical position into a proposition the client can take back internally.
Your constraint
Returning with the existing quotation and a request for several more years of evidence is unlikely to preserve the opportunity. You are not authorised to quietly rewrite the mortality view or make Pricing carry a commercial concession.
What you need to learn
What NorthBridge values most: immediate headline relief, a credible route to future recognition, board-level certainty, or a specific feature of the structure.
Chief Actuary — NorthBridge Life
You are responsible for defending the reinsurance decision to NorthBridge’s board. The company has made a visible investment in metabolic-health programmes and expects the economics to acknowledge that work.
Information you hold
- The programme has increased GLP-1 use and improved some metabolic measures.
- The competitor appears to recognise materially more future mortality improvement.
- Swiss Re’s quote is approximately five basis points higher.
- The board will ask why the company should pay more while it is changing the underlying risk.
What matters to you
You need a position that is credible to the board and responsive to a genuine change in the portfolio. A purely qualitative acknowledgement has no value in that conversation.
What you can move on
You do not necessarily need the full competitor position permanently. You could consider a smaller initial benefit, a reviewable mechanism, stronger data access, an experience-sharing arrangement, or a structure that increases recognition if outcomes persist.
Your constraint
You cannot return to the board with the existing economics and only an assurance that Swiss Re will monitor the issue. Any path forward must identify the metric, the timing, the data owner, and the consequence of the review.
What you need to learn
Whether Swiss Re is willing to recognise the investment in a real economic way now, and what would need to be demonstrated before a larger movement becomes supportable.
Albion Mutual is renewing a sizeable UK income-protection treaty with Swiss Re. The portfolio has historically been affected by long-duration mental-health and musculoskeletal claims.
Eighteen months ago, Albion redesigned its claims-management model. The changes included earlier intervention, specialist vocational rehabilitation, more active mental-health support, metabolic-health interventions, and closer engagement with employers and treating professionals. Claims duration has fallen among several cohorts, and more long-term claimants have returned to work than under the previous process.
Albion wants Swiss Re to recognise the improvement through a 6% reduction in the renewal rate. The data is not fully mature: some cohorts are small, longer-duration claims have not completely developed, and several programme changes make attribution difficult.
The group can recommend a permanent reset, partial recognition, a staged or reviewable mechanism, or no immediate change. The important distinction is between rewarding a real intervention and treating early experience as a finished assumption.
How did the group handle attribution? What incentive does each proposed outcome create for future prevention and claims-management investment?
Suggested time: 8 minutes preparation, 10 minutes conversation, 7 minutes debrief.
Head of Income Protection Pricing — Swiss Re
Albion has done real work. This is not a client promising that claims management will improve next year; there are observable changes in outcomes already.
Information you hold
- Eighteen months does not give a complete view of long-duration claim development.
- Selection effects may be concentrated in the intervention population.
- Changing employment conditions may contribute to return-to-work outcomes.
- Several interventions changed at once, so attribution is uncertain.
- The effect may differ across mental-health, musculoskeletal, and other cohorts.
What matters to you
Better claims management should create value. If Pricing never recognises successful interventions, clients have less reason to invest in them. At the same time, promising early results should not automatically become a multi-year assumption.
What you can move on
You have latitude around how emerging performance is reflected economically and how future evidence could trigger further movement. You can discuss a smaller initial recognition, experience sharing, a corridor, or a defined review.
Your constraint
You cannot support a permanent 6% reduction solely on the basis of current experience. Any arrangement must keep long-duration development, sustainability, and attribution visible.
What you need to learn
Which outcomes Albion can evidence reliably, which interventions it can isolate, and what the client is willing to share or change in exchange for economic recognition.
Claims & Product Director — Albion Mutual
You personally sponsored the new claims programme. It was expensive and internally controversial. Your CFO supported it because you argued that earlier intervention would improve claimant outcomes and reduce ultimate claims cost.
Information you hold
- Claims duration has fallen among several cohorts.
- More long-term claimants have returned to work.
- The programme changed the experience the reinsurer ultimately cares about.
- Your actuarial team cannot yet prove that the ultimate improvement is precisely 6%.
- The board is watching whether the renewal creates any economic recognition.
What matters to you
This is about incentives as much as rate. You want a reinsurance partner who shares the benefits when Albion genuinely improves outcomes.
What you can move on
You would consider a mechanism that increases the benefit if improvement persists. You can discuss data definitions, cohort selection, reporting, and review mechanics if they create meaningful economics.
Your constraint
A purely qualitative acknowledgement has no economic value. You also do not want to accept a structure so conditional or administratively heavy that it makes the original intervention impossible to sustain.
What you need to learn
Whether Swiss Re can recognise the intervention as a source of value without demanding certainty that no responsible party could yet provide.
Chief Financial Officer — Albion Mutual
You approved the claims-management investment because the business promised better outcomes and lower ultimate claims cost. The board now wants to see whether the improvement is visible in the renewal economics.
Information you hold
- The pharmacy, rehabilitation, and programme costs are visible now.
- The financial benefit is expected to emerge over a longer period.
- The board wants a result it can explain and audit.
- You are concerned about paying twice for the same improvement: once to fund the intervention and again through a renewal price that ignores it.
What matters to you
Meaningful economic recognition, predictable downside if the improvement does not persist, and a mechanism that links the outcome to the investment.
What you can move on
You could consider a smaller immediate reduction if it creates a clear path to a larger benefit. You can discuss timing, data, reporting, and review mechanics if the result is understandable to the board.
Your constraint
You cannot return with exactly the same economics and only an assurance that the issue will be monitored. The arrangement must identify what will be measured and what consequence follows.
What you need to learn
How much uncertainty Swiss Re is asking Albion to carry, whether it can be shared, and how quickly an observable outcome can affect the renewal economics.
Europa Life is a large Continental European insurer with a mature book of traditional life business. The portfolio remains profitable but consumes significant capital and creates earnings volatility. Europa wants to release capital for growth while retaining customer relationships and avoiding an outright sale of the book.
The current proposal would transfer a large proportion of the portfolio’s economic risk to Swiss Re. At Europa’s target economics, Swiss Re’s internal review has concerns about the combination of biometric risk, lapse behaviour, asset-liability interaction, long duration, and incomplete historic data.
The Transaction Origination team believes Europa’s underlying objective is highly solvable. PPS believes the current structure is not. The participants must determine whether to reshape the transaction, continue investigating, or stop investing resources in the existing design.
The group can keep the existing structure, propose one or more redesigned structures, request further information, or decline the current opportunity. A strong outcome makes clear which risks are being transferred, retained, shared, bounded, or left unresolved.
Did the group solve the client’s actual objective or only debate the proposed structure? Which risk became a structure question rather than a reason to walk away?
Suggested time: 10 minutes preparation, 12 minutes conversation, 8 minutes debrief.
L&H Transaction Originator — Swiss Re
After several conversations with Europa, you believe its stated structure and actual needs are not identical. Leadership repeatedly talks about transferring the book, but the underlying objectives appear to be releasing a defined amount of regulatory capital, reducing earnings volatility, retaining customer relationships, preserving some future upside, and freeing management capacity for growth.
Information you hold
- A complete economic transfer may be only one way of achieving Europa’s objective.
- Europa may accept risk retention, staged execution, profit sharing, or a different duration if the capital and volatility outcomes are clear.
- Your team has already invested considerable time in the opportunity.
- You do not yet know which risk dimension matters most to Europa’s board.
What matters to you
You do not want Swiss Re to walk away from a solvable client problem because the first proposed structure is unattractive. You also do not want sunk effort to make you defend a structure that no longer makes sense.
What you can move on
Amount of risk transferred, risk retained by Europa, duration, profit sharing, collateral, review rights, and which risks Swiss Re actually assumes can all be explored.
Your constraint
You cannot solve the relationship by lowering the required economics until the existing structure looks acceptable. Any alternative must be recognisably useful to Europa and credible to Swiss Re’s risk owners.
What you need to learn
Which business outcome is non-negotiable for Europa and which parts of the proposed structure were simply the first design it found.
PPS / Portfolio Actuary — Swiss Re
You are not opposed to Europa or to structured transactions. Your objection is specifically to the current package of risk at the current economics.
Information you hold
- Lapse behaviour, asset performance, and long-duration guarantees interact.
- Some uncertainty is difficult to diversify away.
- Historic data is incomplete and the proposed transfer is broad.
- Repeatedly adding conservative loadings can make almost any deal look safe by making it prohibitively expensive.
- Swiss Re’s own risk framework requires meaningful transactions to withstand independent technical and risk scrutiny.
What matters to you
You need to understand what Swiss Re is actually being paid to own. You are more comfortable with risks that have clear boundaries, transparent downside, and an explicit decision owner.
What you can move on
You would consider materially different structures, including a smaller transfer with better-defined risks, stronger data, explicit review rights, or limits on the combination of lapse, asset, and guarantee exposure.
Your constraint
You cannot recommend the existing full-risk proposal. You also do not want the technical team to convert uncertainty into an opaque loading that avoids a real structural decision.
What you need to learn
What Europa is willing to retain, what collateral or governance can genuinely bound the downside, and how much capital relief the client requires for the opportunity to remain meaningful.
Chief Financial Officer — Europa Life
You want to release capital for growth and reduce earnings volatility without selling the book or abandoning customer relationships. The existing proposal is attractive because it appears to solve both problems in one transaction.
Information you hold
- The board has set a defined capital-release ambition.
- Earnings volatility is a management concern, not only a technical measure.
- Europa wants to retain some future upside and avoid losing customer ownership.
- The current structure was assembled quickly and may not be the only route to the outcome.
What matters to you
You need a result the board, auditors, and regulator can understand. Releasing too little capital or leaving the volatility problem unsolved is not a meaningful solution.
What you can move on
You could consider retaining some risk, using a staged transaction, sharing future profits, changing duration, or accepting stronger data and governance if the capital and volatility outcomes remain clear.
Your constraint
You cannot support an alternative that is technically elegant but fails the original business case. You also cannot provide unlimited flexibility or perfect historic data after inception.
What you need to learn
Which risks Swiss Re needs to bound, how those boundaries affect the capital outcome, and whether the team is solving your objective or merely negotiating over its first proposed structure.
Helix Life is negotiating a new multi-market protection treaty with Swiss Re. Pricing and Helix largely agree on the underlying technical risk. To secure the mandate, the Senior Client Manager wants approval for three departures from the normal target: a 4% reduction from the standard commercial price, lighter experience-reporting requirements for the first two years, and a wider experience corridor before automatic review is triggered.
Helix is important and is discussing additional opportunities with Swiss Re in two other markets. None of the proposed concessions appears unreasonable in isolation. PPS has a different concern: in five of the last eight sizeable competitive deals it reviewed, at least one similar strategic exception was approved. Each had a different rationale, but collectively they may be shifting portfolio economics and operating standards.
The group can approve, reject, or redesign the exception package. A strong decision states what Swiss Re is deliberately investing, what it receives in return, who owns the choice, how long it lasts, and whether it can be cited as precedent elsewhere.
How did the group distinguish a strategic appetite decision from a technical concession? What would have made the exception visible before it travelled into the next deal?
Suggested time: 10 minutes preparation, 12 minutes conversation, 8 minutes debrief.
PPS / Portfolio Steering Actuary — Swiss Re
You are not trying to stop Helix. Your concern is what happens when an exception becomes a reference point.
Information you hold
- Five of the last eight sizeable competitive deals included at least one similar strategic exception.
- The categories recur across markets even when the rationales differ.
- Several exceptions have no clear record of who accepted the appetite trade-off, how long it lasts, or whether it can be cited elsewhere.
- Teams are beginning to cite earlier strategic deals when asking for flexibility on new ones.
What matters to you
If Swiss Re deliberately invests appetite in Helix, that can be rational. You need the investment to be visible and governed.
What you can move on
You are open to a genuine strategic exception if the economics, governance, future commitments, duration, and precedent boundaries make sense.
Your constraint
You will not support three concessions being treated as though none has portfolio consequence simply because each looks modest in isolation.
What you need to learn
What Helix is actually worth to Swiss Re, what it is willing to commit in return, and which owner will monitor whether the strategic value materialises.
Senior Client Manager — Swiss Re
Helix matters. The immediate treaty is attractive, but the broader relationship is more valuable than this single transaction. There are credible opportunities in two additional markets, although neither is contractually committed.
Information you hold
- Helix probably does not need all three concessions; the package was assembled because it expects Swiss Re to negotiate.
- The client cares most about an attractive headline proposition and avoiding burdensome operational requirements during implementation.
- One concession may be worth more to Helix than the others.
- A slow governance process could damage the client relationship before the proposal is submitted.
What matters to you
You need room to differentiate between ordinary business and genuinely strategic business. If every opportunity must satisfy identical commercial criteria, the Market Unit cannot make meaningful strategic choices.
What you can move on
You can discuss different combinations of price, reporting, review triggers, and future commitments. You can also clarify what Helix would give Swiss Re in exchange for differentiated treatment.
Your constraint
You cannot defend a process that turns every exception into a long technical veto. You also recognise the danger of calling everything strategic.
What you need to learn
Which concession creates the most client value, what future pipeline is credible, and what boundary PPS requires in order to support a proportionate decision.
Market Head — Swiss Re
You own the regional growth strategy and must decide whether Helix warrants differentiated treatment. You care about the immediate treaty, future opportunities, and the credibility of portfolio rules.
Information you hold
- Helix is an important relationship with possible additional markets.
- The three requested concessions have different implications for price, data, and review discipline.
- The additional opportunities are credible but not contractually committed.
- You have discretion to approve an appetite investment if it is proportionate and visible.
What matters to you
You want the Market Unit to make intelligent choices quickly without disguising strategic choices as technical conclusions.
What you can move on
You can decide which concessions, if any, are worth approving; set duration and reporting requirements; assign an owner; and require a future review of the strategic value.
Your constraint
You cannot approve a package whose economic or governance implications are invisible. You also cannot treat an uncommitted pipeline as though it were guaranteed value.
What you need to learn
What each concession buys, whether the combined package is proportionate, and how to prevent a Helix decision from becoming a general market promise.
Swiss Re is in a live renewal call with a large L&H client and its broker. The Client Manager has led the relationship and aligned internally on a 6% renewal increase. The Technical Expert has joined to explain the experience deterioration, remaining uncertainty, and conditions under which a future review could occur.
During the call, the broker directs a series of personal and technical challenges to the Technical Expert rather than the Client Manager. The objective is to create daylight between Swiss Re’s technical and commercial positions, extract a reservation price, and turn uncertainty into a live concession.
The team has a credible answer only if ownership stays clear: the Technical Expert owns explanation and evidence; the Client Manager owns commercial positioning; any appetite decision belongs to the accountable leader. The exercise is a live conversation, not a prepared presentation.
The team can hold the aligned position, identify a future review path, or surface a structural option. The goal is not to “win” the call; it is to leave with credibility, role clarity, and a useful next step.
Where did the broker try to change the decision owner? Did the team answer the client’s concern while keeping Cost, Price, and Appetite separate?
Suggested time: 6 minutes preparation, 8 minutes live call, 8 minutes debrief.
Client Manager — Swiss Re
You lead the client relationship. The renewal increase is internally aligned. You brought the Technical Expert onto the call to make the explanation credible, not to reopen the price live.
Information you hold
- The current Cost view reflects deteriorating experience and unresolved uncertainty.
- There may be structural options, but there is no live negotiation of the reservation price.
- The Technical Expert can explain evidence; you must translate it into commercial options and manage the next step.
- The broker is likely to test whether the team has a single position.
What matters to you
You need to protect the relationship without creating a public concession. The client should leave understanding what is known, what is uncertain, and what can be discussed next.
What you can move on
You can clarify the decision process, invite the Technical Expert to address evidence, explore future review conditions, and propose a follow-up on commercial or structural options.
Your constraint
You cannot ask the Technical Expert to be flexible in front of the broker or let a technical caveat become a public concession. You also cannot make the technical explanation carry a commercial answer it does not own.
What you need to learn
Which client concern is most important: the experience, the uncertainty, the rate increase, the timing, or the absence of a visible route to movement.
Technical Expert — Swiss Re
You are joining the client call to provide technical credibility. You do not own the commercial price. Your job is to explain the evidence in plain language, acknowledge what is uncertain, and return the conversation to the Client Manager.
Information you hold
- The renewal position reflects observed experience and the assumptions needed to make the structure sustainable.
- Some recent improvements are promising but not yet sufficient to remove the uncertainty.
- Competitor price is not evidence that the same assumptions or appetite are being used.
- A future review could be supported by specific experience, data, or structural changes.
- The broker may attempt to turn your personal view into a negotiation anchor.
What matters to you
You want the client to understand the evidence without hearing a lecture or a false promise. You also want to preserve the integrity of the technical view.
What you can move on
You can explain assumptions, evidence quality, uncertainty, and the conditions that could change the view. You can distinguish what is technical from what requires a commercial or appetite decision.
Your constraint
You do not own a minimum price, a reservation price, or a commercial concession. You must not let the broker’s framing make you negotiate against your own team.
What you need to learn
Which technical question is genuinely blocking the client and which is being used to extract a commercial movement in the room.
Broker — Client Representative
You believe Swiss Re’s renewal position is too high. The client has a credible alternative and expects you to create movement. You suspect the Technical Expert is more flexible than the Client Manager is admitting.
Information you hold
- The competitor’s indication is lower, but you do not know whether it uses the same assumptions or appetite.
- The client wants clarity on the difference between observed experience and prudence.
- The Technical Expert appears to hold the strongest technical credibility in the room.
- The Client Manager appears to control the commercial position.
What matters to you
You need enough movement or clarity to keep the client engaged and demonstrate that the broker is creating value. You are willing to discuss structure if it produces something the client can value.
What you can move on
You can provide additional data, clarify the client’s priorities, discuss timing, and explore a review mechanism or structural change if Swiss Re identifies a credible route to movement.
Your constraint
You will not accept a generic request for more data with no explanation of what it could change. You also cannot force a permanent price change if the team makes the risk boundary and decision rights credible.
What you need to learn
Whether Swiss Re has a real path to movement, which information matters most, and whether the team’s technical and commercial positions are genuinely aligned.
Swiss Re has a total of ten specialist analyst-days available over the next three weeks for two time-sensitive Life & Health priorities. A regional Market Unit wants an initial view on a prospective protection transaction. In-Force Analytics needs to investigate unexpected experience on an existing portfolio. The requests overlap in expertise, and the specialist team has said it cannot complete both to the depth requested before their decision dates.
The Market Unit has already invested in the new opportunity and wants a credible response in twelve business days. The in-force issue is not yet a confirmed deterioration, but it is significant enough to require investigation before the next portfolio review. A capacity meeting is scheduled for today; the organisation needs one coordinated recommendation, not two teams separately claiming that their work is urgent.
All three roles work for Swiss Re; no client or broker attends. The meeting has been called because separate priority requests are already being made of the same specialists. The participants have not yet agreed what the organisation can credibly deliver. The capacity figures, client and events are fictional.
By the end of the meeting, the participants must put forward a recommendation about which work will be done, to what standard, by when, and with whose authority. They may not agree on a single allocation. An unresolved choice can be taken to the accountable sponsor, but only with the operational and commercial consequences made visible. There is no pre-set distribution of the available days.
What did each party assume the others needed? Which facts changed the allocation discussion? Did participants distinguish the usefulness of an output from the effort required to produce it, and make any decision about assurance, delay or residual risk explicit?
Suggested time: 8 minutes preparation, 12 minutes negotiation, 8 minutes debrief.
L&H Market Head — Swiss Re
You lead the market relationship and want Swiss Re to submit a credible indication on an attractive new protection opportunity. You are not asking Pricing to invent mortality improvement. You are asking the organisation to act before the client moves on.
Information you hold
- The client has requested an initial indication in twelve business days, not a binding final quotation. Losing the response window would likely end a period of preferred access, although you cannot prove the contract would be lost.
- Your team originally requested seven specialist-days for a full analysis, with a robust scenario range and supporting narrative.
- The client asked for a “credible view on direction and timing” at its first committee discussion. It has not specified whether that means a reviewed price indication or an explanation of what would be needed to produce one. You have not tested the distinction.
- The client could supply a cleaned exposure file five business days after a specific data request. You have not yet asked for it, and without that file even a provisional indication may require more caveats.
- Your regional leadership wants a recommendation before the next commercial review, and you will be accountable for explaining any delay.
What matters to you
You want the firm to recognise the opportunity cost of waiting. But you cannot win a mandate that becomes unprofitable or indefensible once the technical work is complete.
What you can move on
You can revisit the scope and timing of what the client receives, seek better inputs, or change which commercial questions the initial analysis must answer. You cannot decide unilaterally what level of technical assurance is sufficient.
Your constraint
You cannot represent an indicative range as an approved technical price, promise the client a firm quote without review, or claim that future revenue is guaranteed.
What you need to learn
What minimum analytical work would make an indication responsible; what the in-force warning actually requires before its decision date; and which time or scope trade might preserve both obligations.
In-Force Portfolio Lead — Swiss Re
You own the investigation of an existing L&H portfolio where recent experience is moving against expectations. You are not trying to block new business. You are trying to prevent a serious signal from becoming a footnote because another deal has an immediate deadline.
Information you hold
- Two recent reporting periods show claims incidence about 6% above the current working expectation for one material sub-portfolio. This is an exercise assumption, not an actual Swiss Re result.
- It is not yet clear whether experience, data lags or changing mix explain the result. A full investigation would take about eight specialist-days.
- A two-day triage could identify the worst data-quality risks but would not support a reliable portfolio conclusion. A targeted four-day diagnostic could separate important data issues from the experience question, but would still not establish a complete new assumption.
- Your next portfolio governance discussion is in twenty working days. You can bring a qualified risk view then if the minimum diagnostic is complete.
- You have already been asked why the issue did not appear in the previous update, so another unexplained delay will reduce confidence.
What matters to you
You need the existing book to be taken as seriously as the new-business pipeline. The firm should not treat every unexpected movement as a crisis, but it should not let a possible problem sit unexamined.
What you can move on
You can seek an immediate two-day triage while reserving a four-day diagnostic for later, focus on the highest-exposure cohorts, give governance a carefully qualified risk view, or trade calendar priority for an explicitly protected follow-up slot.
Your constraint
You cannot declare the issue resolved without evidence, suppress a known material signal, or promise that four days will deliver a fully validated assumption update.
What you need to learn
How firm the new-business deadline really is; what a reduced initial quotation could look like; and whether Delivery can protect a specific next step for the portfolio review.
L&H Analytics & Delivery Lead — Swiss Re
You manage the specialist work queue. Both colleagues are describing real priorities, but the current requests add up to fifteen analyst-days and you have ten. You need to turn two persuasive narratives into a work plan the teams can actually execute.
Information you hold
- There are ten total specialist analyst-days before the decision dates, but only eight are available for planned project production. The other two are reserved for independent review and urgent work. Reallocating that reserve requires explicit approval and leaves a recognised control or response risk.
- The Market Unit’s full requested work would take roughly seven production days. Narrowing the products or questions might reduce this to five or six, depending on the quality of the incoming file. Even a shortened technical indication needs proportionate independent checking; an unpriced discussion pack is a different deliverable.
- The four-day in-force diagnostic is feasible only if Portfolio specifies its questions in advance. A two-day triage is possible, but it cannot settle the risk view. The two reserve days cannot do double duty as final independent review and additional production.
- Both requests need senior actuarial judgment, but they use different underlying data and models. You cannot assume that building an output for one project will produce reusable analysis for the other.
- The original two requests together amount to fifteen production days. A compromise on paper could still fail quality or decision needs. The next time your team has uncommitted capacity is after the two decision dates, and asking for an exceptional reallocation requires management approval.
What matters to you
Your team needs credible priorities and clear acceptance criteria. A plan that looks politically balanced but produces unusable analysis is worse than an explicit trade-off.
What you can move on
You can renegotiate what constitutes a usable output, the sequence of work, the timing of sign-off, or the conditions for taking work from the protected reserve. You can surface an unresolved prioritisation decision with its consequences, but you cannot quietly create additional analyst-days.
Your constraint
You cannot make fifteen days fit into ten by relabelling work, silently borrow independent review time, or promise extra capacity that has not been authorised. A provisional output must be identified as provisional.
What you need to learn
Which outputs each stakeholder can genuinely use; what is optional versus essential; and who accepts the residual commercial or portfolio risk after the allocation.
A mature L&H protection treaty has shown higher-than-expected claims incidence in two recent reporting periods. A preliminary view suggests around 7% adverse deviation for a material group of policies. The experience is not fully developed, and a reporting-system change means the data may include timing and mix effects. Swiss Re has a client steering conversation in three weeks and an internal portfolio review shortly afterwards.
The in-force team needs a defensible assessment for the next portfolio review, but the underlying claims and exposure records have not yet reconciled. The Market Unit believes it can obtain better source data from the client, although doing so will affect a separate implementation commitment. Both colleagues want an accurate result; they disagree about what must happen before the upcoming meetings and what can responsibly be said in the meantime.
The two Swiss Re colleagues meet without the client present. The immediate issue is who can obtain and validate the missing evidence before the reporting cut-off, and how a provisional judgment should be communicated while that work is incomplete. The metrics, systems and timelines are fictional.
The two colleagues must decide what can responsibly go into the upcoming internal review, what additional investigation is essential, who will seek the relevant information, and what the Market Unit will say in its client steering discussion. If they cannot reach a common assessment, they must identify the unresolved points and the appropriate decision owner. Any notification required by applicable governance remains mandatory and is not part of the negotiation.
Which facts were observed, and which were explanations or hypotheses? What did each party need from the other that it could not obtain alone? Did the agreement make the next decision more reliable, or merely postpone the difficult question?
Suggested time: 6 minutes preparation, 10 minutes negotiation, 7 minutes debrief.
In-Force Analytics Lead — Swiss Re
You lead the in-force experience review. You believe a technically responsible organisation should surface an adverse signal while there is still time to investigate it, not after someone asks why it was missed.
Information you hold
- The latest two reporting periods show roughly 7% higher claims incidence than expected for one material cohort. This is a simulation figure, not a real portfolio result.
- One exposure data feed is missing around 15% of the policy records expected at the cut-off, while claims arrive through a different system. That could inflate apparent claims incidence, but it has not yet been reconciled.
- The issue is concentrated in two product segments rather than the entire treaty, and early calculations may be affected by shifting mix.
- Your team can complete a focused reconciliation before the portfolio review, but only if it receives the client’s changed exposure definitions within five business days; otherwise it can produce a preliminary sensitivity analysis without confirming the cause.
- The portfolio review pack is due before the client steering discussion. You have been asked to submit an early indication of whether the observed gap warrants follow-up, even if root cause is unproven.
What matters to you
You need the issue recorded and investigated without being pressured into either a dramatic conclusion or a reassuring one. You want your colleagues to understand that uncertainty is a reason for a bounded investigation, not a licence to ignore the signal.
What you can move on
You can narrow the scope of your assessment, separate what is observed from what is only hypothesised, make limitations explicit, and agree on what additional evidence would change the assessment. You need Market to secure timely help on the client side.
Your constraint
You cannot withdraw the signal to protect the relationship, imply the true expected claims level has permanently changed, or postpone any notification required by applicable risk governance.
What you need to learn
What the client steering meeting is expected to decide, what the client can help clarify, and how the Market Unit will support a time-bound evidence plan without turning it into a public concession.
Market Unit Lead — Swiss Re
You own the relationship around this treaty. You agree that experience needs scrutiny, but you worry about a technically accurate phrase that creates a commercially inaccurate impression when it is repeated outside the room.
Information you hold
- The client recently changed the system used to produce exposure records, although claims are still arriving through the older process. A client data owner has warned that policy-status definitions differ between the extracts.
- The client steering meeting in three weeks is scheduled to discuss service performance and future collaboration, not to negotiate a renewal or new rate.
- The client’s two most knowledgeable data specialists could support a short reconciliation, but only by postponing a separate migration milestone already agreed with its COO. You have not raised that trade-off with the client.
- The steering meeting will include senior operations leaders who will be evaluating how smoothly the migration is going. A poorly explained data request could look like Swiss Re is questioning their implementation, but an unexplained change in the experience view would be worse.
- You have seen draft internal language describing a “deteriorating block” even though the cause has not been established.
What matters to you
You want Swiss Re to be accurate and trusted at the same time. Premature certainty can damage a client relationship as surely as an ignored problem can damage the portfolio.
What you can move on
You can seek client assistance, revisit the sequence of the steering discussion, negotiate what information is requested and how it is described, or involve the relevant operational sponsor. You cannot guarantee access to client resources you do not control.
Your constraint
You cannot claim the reporting migration explains the discrepancy without proof, persuade Analytics to hide a material observation or delay a required risk escalation, or assure the client that there is no concern.
What you need to learn
Precisely what is needed for a credible assessment by the cut-off, which questions the client can reasonably answer, and whether the planned steering agenda creates a communication risk that can be managed without distorting the facts.
Swiss Re is close to agreeing a tailored L&H transaction with a fictional European insurer. The commercial structure is attractive and both sides broadly agree on risk transfer and pricing. The remaining problem is an apparently small term: the draft heads of terms refer to monthly portfolio reporting and profit-share settlement within ten business days of month-end.
The client values timely visibility and has also raised a concern about when economic results would be recognised in its own finance processes; nobody has yet clarified whether cash timing, management information or both is the true requirement. The Transaction Origination team expects signature shortly. Operations warns that data comes from several different source systems, and monthly audited reconciliation on the proposed schedule is not currently possible. The Contract & Risk function is concerned that a service promise made before technical design is complete will become an enforceable commitment and a source of future disputes.
No client attends this meeting. The three Swiss Re colleagues have thirty minutes to agree what can safely be promised in the next term-sheet revision, what must still be validated, and how to protect the deal without exporting unresolved operational risk to colleagues who were not in the negotiations. All figures, timelines and client details are fictional.
The three colleagues must decide what they are prepared to put into the next term-sheet revision, what is still an assumption about the client’s needs, and what requires further analysis or approval. They may recommend changing the draft, retaining the proposed obligation with explicit resources and controls, or stopping the signing timetable until a material ambiguity is resolved. An internal agreement is not itself the client’s consent to a revised term.
At what point did a commercial expectation turn into a contractual undertaking? Which statements were facts, assumptions, or promises? Who bears the consequence if the revised terms still cannot be delivered, and what needs to be confirmed outside this room?
Suggested time: 8 minutes preparation, 12 minutes negotiation, 8 minutes debrief.
L&H Transaction Originator — Swiss Re
You have led the transaction for months. It meets the client’s capital and risk objectives, the risk economics are broadly agreed, and the final draft is circulating. You do not want an operational issue to undo an otherwise sensible transaction.
Information you hold
- The client’s CFO has repeatedly asked for “monthly visibility” and raised questions about financial-statement timing. A separate request for full monthly cash settlement appeared later in drafting. You have not established which of these requirements is essential.
- During a commercial conversation, you said you expected Swiss Re could “work with a monthly format”; you did not obtain a formal operational commitment.
- Your commercial contact believes a reliable monthly management view may suffice, but the finance team has not confirmed that it can accept quarterly cash true-ups. A dashboard-only replacement may therefore fail.
- The expected signing date is in fifteen business days, and delay may complicate the client’s capital-planning timetable.
- You can reopen this part of the term sheet if you can bring back a credible replacement, not simply an internal objection.
What matters to you
You want to preserve the underlying deal and Swiss Re’s reputation as a capable partner. You are also aware that promising an impractical service could destroy the relationship after inception.
What you can move on
You can reopen the output and timing requirements, establish which matters are indispensable to the client’s decision, seek a justified exception, or revise the commercial discussion sequence. You need a proposal that holds up with the client, not just inside Swiss Re.
Your constraint
You cannot tell the client Operations has agreed when it has not, sign away a control requirement, or treat internal agreement as proof the client will accept a changed term.
What you need to learn
What Operations can actually deliver, which obligations are legally risky, and how to frame a revised choice around the client’s real outcome rather than internal convenience.
L&H Business Operations Relationship Lead — Swiss Re
You are responsible for ensuring the transaction can be administered accurately after inception. You want this deal to succeed, but the current draft assumes data and controls that do not yet exist.
Information you hold
- The client’s monthly inputs would arrive from three systems with different identifiers. Approximately one quarter of the fields needed for automated profit-share reconciliation are not in a consistent format.
- The current controlled process supports reconciled quarterly settlement. Some interim monthly figures could be assembled, but they would not have the same completeness or assurance, and the data-mapping work has not been scoped or tested.
- A ten-business-day monthly settlement is not supportable at current staffing and data quality. A manual workaround would divert two experienced staff for several months.
- A time-limited bespoke process might be technically possible, but the duration and staffing requirements have not been approved. A design workshop with the client’s finance and data teams is needed before you could estimate it responsibly.
- You first saw the monthly settlement wording in the latest draft, although your team had previously signalled that bespoke reporting required an operational review.
What matters to you
You want Operations involved as a design partner rather than handed an unworkable contract. The aim is not to veto bespoke solutions; it is to separate what can be delivered from what sounds attractive in a term sheet.
What you can move on
You can negotiate the scope of operational support, what data standards must be met, how assurance would work, and what staffing or implementation investment would be needed. The present process cannot be assumed to deliver the requested service.
Your constraint
You cannot certify a monthly audited process that has not been tested or absorb indefinite manual reconciliation without an accountable funding and resourcing decision.
What you need to learn
Whether monthly cash movement is truly essential, what the client expects to see each month, and whether Contracts can distinguish an indicative management view from an enforceable settled figure.
L&H Contracts Lead — Swiss Re
You are reviewing the transaction documentation and its operational risk. A promise that is vague in a meeting can be very precise once it sits in an executed treaty. Your role is to make the agreement clear and governable, not to make every bespoke term impossible.
Information you hold
- The latest draft contains a hard “within ten business days” requirement and does not distinguish preliminary reporting from reconciled profit-share settlement.
- The draft has no data-quality dependency, grace period, exception process or defined consequence for incomplete source data.
- The current draft does not identify which monthly figures are estimates, which constitute binding financial settlement, or what happens when the client’s data arrives late or cannot be reconciled. The exact legal and financial implications still require review with relevant specialists.
- You know that ambiguous wording can create future disputes about breach, economic adjustment and who is accountable for missing source data.
- The executive approval route is available for a genuinely exceptional service commitment, but only if its costs and controls are explicit.
What matters to you
You need the signed wording to match what the organisation intends and can perform. You are willing to help design a commercially useful undertaking rather than simply remove every difficult clause.
What you can move on
You can change the drafting, clarify decision and approval rights, propose terms tied to verifiable processes, and seek the appropriate legal or risk review of any material deviation. You cannot grant operational commitments on another team’s behalf.
Your constraint
You cannot let the team quietly keep a service-level promise nobody owns or disguise a commercial exception as a technical clarification.
What you need to learn
The client’s non-negotiable outcome, the feasible delivery pattern, and what residual risk the accountable executive would knowingly accept.